Abstract
New insights into the mechanism of dopaminergic (DA) nigrostriatal neuron degeneration and regeneration in experimental studies in animal models of Parkinson’s disease (PD) have opened up the discussion about novel therapeutic strategies such as cell-based therapies and neuroprotection of DA neurons. These cellular and molecular approaches aim at preventing or slowing down the progressive degeneration of DA neurons and/or replacing the lost ones. Here, a brief overview of basic principles and current strategies of these novel restorative approaches is discussed in light of experimental results and possible clinical applications.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Aron L, Klein R (2011) Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci 34:88–100
Backlund EO, Granberg PO, Hamberger B, Knutsson E, Martensson A, Sedvall G, Seiger A, Olson L (1985) Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 62:169–173
Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436–1438
Blandini F, Porter RH, Greenamyre JT (1996) Glutamate and Parkinson’s disease. Mol Neurobiol 12:73–94
Brundin P, Dunnett S, Bjorklund A, Nikkhah G (2001) Transplanted dopaminergic neurons: more or less? Nat Med 7:512–513
Capetian P, Döbrössy M, Winkler C, Prinz M, Nikkhah G (2011) To be or not to be accepted: the role of immunogenicity of neural stem cells following transplantation into the brain in animal and human studies. Semin Immunopathol 33:619–626
Carvalho GA, Nikkhah G (2001) Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions. Exp Neurol 171:405–417
Chevalier G, Deniau JM (1990) Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 13:277–280
Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13:171–182
Döbrössy M, Busse M, Piroth T, Rosser A, Dunnett S, Nikkhah G (2010) Neurorehabilitation with neural transplantation. Neurorehabil Neural Repair 24:692–701
Dyson SC, Barker RA (2011) Cell-based therapies for Parkinson’s disease. Expert Rev Neurother 11:831–844
Falkenstein G, Rosenthal C, Reum T, Morgenstern R, Döbrössy M, Nikkhah G (2009) Pattern of long-term sensorimotor recovery following intrastriatal and – accumbens DA micrografts in a rat model of Parkinson’s disease. J Comp Neurol 515:41–55
Feger J, Hassani OK, Mouroux M (1997) The subthalamic nucleus and its connections. New electrophysiological and pharmacological data. Adv Neurol 74:31–43
Foley P, Riederer P (1999) Pathogenesis and preclinical course of Parkinson’s disease. J Neural Transm Suppl 56:31–74
García J, Carlsson T, Döbrössy M, Nikkhah G, Winkler C (2011) Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia. Neurobiol Dis 43:576–587
Gash DM, Zhang Z, Gerhardt G (1998) Neuroprotective and neurorestorative properties of GDNF. Ann Neurol 44:S121–S125
Guridi J, Herrero MT, Luquin MR, Guillen J, Ruberg M, Laguna J, Vila M, Javoy-Agid F, Agid Y, Hirsch E, Obeso JA (1996) Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 119(Pt 5):1717–1727
Guridi J, Obeso JA (1997) The role of the subthalamic nucleus in the origin of hemiballism and parkinsonism: new surgical perspectives. Adv Neurol 74:235–247
Halliday G, Lees A, Stern M (2011) Milestones in Parkinson’s disease – clinical and pathologic features. Mov Dis 26:1015–1021
Hassani OK, Mouroux M, Feger J (1996) Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 72:105–115
Isacson O (2009) Cell therapy ahead for Parkinson’s disease. Science 326:1060
Kearns CM, Cass WA, Smoot K, Kryscio R, Gash DM (1997) GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J Neurosci 17:7111–7118
Koller W, Wilkinson S, Pahwa R et al (1998) Surgical treatment options in Parkinson’s disease. In: Bakay R (ed) Neurosurgery clinics of North America: surgical treatment movement disorders. W. B. Saunders Company, Philadelphia, pp 295–306
Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 14(5):504–506
Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 290:767–773
Lang AE, Lozano AM (1998) Parkinson’s disease. Second of two parts. N Engl J Med 339:1130–1143
LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A (2011) AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10:309–319
Levy R, Hazrati LN, Herrero MT, Vila M, Hassani OK, Mouroux M, Ruberg M, Asensi H, Agid Y, Feger J, Obeso JA, Parent A, Hirsch EC (1997) Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states. Neuroscience 76:335–343
Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14:501–503
Lindvall O, Björklund A (2011) Cell therapeutics in Parkinson’s disease. Neurotherapeutics 8:539–548
Lindvall O, Kokaia Z (2010) Stem cells in human neurodegenerative disorders – time for clinical translation? J Clin Invest 120:29–40
Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, Lindholm T, Bjorklund A, Leenders KL, Rothwell JC, Frackowiak R, Marsden D, Johnels B, Steg G, Freedman R, Hoffer BJ, Seiger A, Bygdeman M, Strömberg I, Olson L (1989) Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 46:615–631
Maciaczyk J, Singec I, Maciaczyk D, Nikkhah G (2008) Combined use of BDNF, ascorbic acid, low oxygen, and prolonged differentiation time generates tyrosine hydroxylase-expressing neurons after long-term in vitro expansion of human fetal midbrain precursor cells. Exp Neurol 213(2):354–362
Madrazo I, Drucker-Colin R, Diaz V, Martinez-Mata J, Torres C, Becerril JJ (1987) Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson’s disease. N Engl J Med 316:831–834
Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E (2011) Priorities in Parkinson’s disease research. Nat Rev Drug Discov 10:377–393
Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O (2008) Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years. Nat Med 14:507–509
Nikkhah G (2001) Transplantation of embryonic dopamine neurons for severe Parkinson’s disease: potential and pitfalls. Brain Res Bull 56:509
Nikkhah G, Falkenstein G, Rosenthal C (2001) Restorative plasticity of dopamine neuronal transplants depends on the degree of hemispheric dominance. J Neurosci 21:6252–6263
Nikkhah G, Rosenthal C, Falkenstein G, Roedter A, Papazoglou A, Brandis A (2009) Microtransplantation of dopaminergic cell suspensions: further characterization and optimization of grafting parameters. Cell Transplant 18:119–133
Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451:205–212
Olanow CW (1997) Attempts to obtain neuroprotection in Parkinson’s disease. Neurology 49:S26–S33
Olanow CW, Jenner P, Brooks D (1998) Dopamine agonists and neuroprotection in Parkinson’s disease. Ann Neurol 44:S167–S174
Olanow CW, Koller W, Goetz CG, Stebbins GT, Cahill DW, Gauger LL, Morantz R, Penn RD, Tanner CM, Klawans HL, Shannon KM, Comella CL, Witt T (1990) Autologous transplantation of adrenal medulla in Parkinson’s disease. 18-month results. Arch Neurol 47:1286–1289
Olanow CW, Mytilineou C, Tatton W (1998) Current status of selegiline as a neuroprotective agent in Parkinson’s disease. Mov Disord 13(Suppl 1):55–58
Quinn N (1997) Parkinson’s disease: clinical features. In: Quinn N (ed) Clinical neurology. Parkinsonism. Bailliere Tindall, London, pp 1–13
Rodriguez MC, Obeso JA, Olanow CW (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson’s disease: a target for neuroprotection. Ann Neurol 44:S175–S188
Roedter A, Winkler C, Samii M, Nikkhah G (2000) Complex sensorimotor behavioral changes after terminal striatal 6-OHDA lesion and transplantation of dopaminergic embryonic micrografts. Cell Transplant 9:197–214
Schapira A (1997) Pathogenesis of Parkinson’s disease. In: Quinn N (ed) Clinical neurology. International practice and research. Parkinsonism. Bailliere Tindall, London, pp 15–36
Singec I, Jandial R, Crain A, Nikkhah G, Snyder EY (2007) The leading edge of stem cell therapeutics. Annu Rev Med 58:313–328
Singec I, Knoth R, Meyer RP, Maciaczyk J, Volk B, Nikkhah G, Frotscher M, Snyder EY (2006) Defining the actual sensitivity and specificity of the neurosphere assay in stem cell biology. Nat Methods 3:801–806
Smith GS, Laxton AW, Tang-Wai DF, McAndrews MP, Diaconescu AO, Workman CI, Lozano AM (2012) Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. Arch Neurol. doi:10.1001/archneurol.2012.590
Wichmann T, Bergman H, DeLong MR (1994) The primate subthalamic nucleus. I. Functional properties in intact animals. J Neurophysiol 72:494–506
Wichmann T, Bergman H, DeLong MR (1994) The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol 72:521–530
Winkler C, Kirik D, Bjorklund A (2005) Cell transplantation in Parkinson’s disease: how can we make it work? Trends Neurosci 28:86–92
Winkler C, Sauer H, Lee CS, Björklund A (1996) Short-term GDNF treatment provides long-term rescue of lesioned nigral dopamine neurons in a rat model of Parkinson’s disease. J Neurosci 16:7206–7215
Acknowledgments
Parts of the work presented here have been supported by grants from the Deutsche Forschungsgemeinschaft (Ni 330), the Graduate School Freiburg (DFG 843), the Weber Petri Foundation, the German Parkinson Foundation and the European Commission under the 7th Framework Programme — HEALTH — Collaborative Project Transeuro (Contract n 242003).
Conflict of InterestNo potential conflict of interest relevant to this article was reported.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Wien
About this paper
Cite this paper
Nikkhah, G. (2013). Restorative Strategies for the Dopaminergic Nigrostriatal Projection Pathway. In: Nikkhah, G., Pinsker, M. (eds) Stereotactic and Functional Neurosurgery. Acta Neurochirurgica Supplement, vol 117. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1482-7_13
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1482-7_13
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1481-0
Online ISBN: 978-3-7091-1482-7
eBook Packages: MedicineMedicine (R0)